Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy of the triplet therapy with venetoclax, azacitidine and gilteritinib for the treatment of FLT3-ITD mutated AML patients with refractory/relapsed disease or persistent minimal residual disease bridging to allogeneic hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

CLChen LiangDYDonglin YangMHMingzhe Han

Discussion

Loading...

Member takes

Overview

Observational analysis found triplet therapy improved remission rates in acute myeloid leukemia patients, suggesting new avenues for treatment.

Key Points

  • 81.3% of patients achieved CR/CRi after one cycle of triplet therapy, indicating effective treatment for high-risk populations.
  • 1-year overall survival and relapse-free survival rates were 83.3% and 75.0%, respectively, highlighting clinical effectiveness.
  • Patients underwent hematopoietic stem cell transplantation with no treatment-related mortality observed during the study.
  • These findings may support using triplet therapy before hematopoietic stem cell transplantation, especially for patients with minimal residual disease.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e535https://doi.org/10.1182/blood-2025-2519
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3-mutated Acute Myeloid Leukemia2025 · 1 citations
  2. 2Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations
  3. 3Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients2025 · 1 citations
  4. 4Gilteritinib in FLT3‐mutated acute myeloid leukemia: A real‐world Italian experience2025 · 6 citations
  5. 5A Phase 2 study of sequential administration of gilteritinib after MEC chemotherapy in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia in adults: Japan adult leukemia study group (JALSG) RR-FLT3-AML220 study2025